Photosensitive Drugs

Medicare covers verteporfin (a photosensitive drug) for ocular photodynamic therapy when furnished intravenously incident to a physician's service for patients with neovascular age-related macular degeneration whose initial fluorescein angiogram shows predominantly classic subfoveal CNV occupying >=50% of the lesion. Follow-up assessments must be documented by OCT or FA. Verteporfin is non-covered for other AMD indications and non-AMD use is subject to local Medicare Administrative Contractor discretion.

"Verteporfin used with ocular photodynamic therapy (OPT) is covered for patients with neovascular age-related macular degeneration (AMD) when the initial fluorescein angiogram (FA) demonstrates pred..."

Sign up to see full coverage criteria, indications, and limitations.